v3.26.1
Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Significant Accounting Policies [Line Items]            
Collaboration revenue $ 243,745   $ 163,616   $ 494,892 $ 421,500
Research and development expenses:            
Clinical product candidates [1] 3,536,620       6,338,510  
Preclinical product candidates [1]     2,486,265     6,508,641
Sponsored research [1] 146,250   282,805   242,500 485,215
Internal research and development expenses, including stock-based compensation [1] 1,347,797   894,033   2,546,237 1,883,323
Total research and development expenses [1] 5,030,667   3,663,103   9,127,247 8,877,179
General and administrative expenses:            
Employee related costs 562,435   684,844   1,294,108 1,368,927
Stock-based compensation 512,246   677,926   2,272,114 1,373,319
Other general and administrative expenses [2] 1,180,922   1,545,421   2,471,358 2,879,835
Total general and administrative expenses 2,255,603   2,908,191   6,037,580 5,622,081
In-process research and development 1,656       11,656  
Depreciation 2,807   6,840   5,614 13,680
Other income (408,728)   (319,541)   (841,955) (689,706)
Net loss $ (6,638,260) $ (7,206,990) $ (6,094,977) $ (7,306,757) $ (13,845,250) $ (13,401,734)
[1] External research and development expenses include: fees paid to CROs, CMOs and research laboratories, process development, manufacturing and clinical development activities. Any internal research and development expenses associated with clinical product candidates are captioned as internal research and development expenses.
[2] Other general and administrative costs include professional fees, investor relation costs, taxes, licenses, and insurance.